We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

220 hedge funds and large institutions have $2.55B invested in Agios Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 68 increasing their positions, 69 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

24% more capital invested

Capital invested by funds: $2.05B → $2.55B (+$494M)

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

3% more funds holding

Funds holding: 214 → 220 (+6)

2.77% more ownership

Funds ownership: 106.52% → 109.29% (+2.8%)

9% more call options, than puts

Call options by funds: $85.2M | Put options by funds: $78.2M

1% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 69

Holders
220
Holders Change
+6
Holders Change %
+2.8%
% of All Funds
2.89%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
43
Increased
68
Reduced
69
Closed
35
Calls
$85.2M
Puts
$78.2M
Net Calls
+$7.06M
Net Calls Change
+$4.49M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$77.1M
2
PBA
Paradigm Biocapital Advisors
New York
+$57.6M
3
TCM
TCG Crossover Management
California
+$27.6M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$18.6M
5
EAM
Erste Asset Management
Austria
+$16.5M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$31.8M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$23.2M
3
Citadel Advisors
Citadel Advisors
Florida
-$22.2M
4
O
OrbiMed
New York
-$18.6M
5
Marshall Wace
Marshall Wace
United Kingdom
-$17.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fifth Third Bancorp
201
Fifth Third Bancorp
Ohio
$1.2K +$1.13K +30 New
MCM
202
MAI Capital Management
Ohio
$1K -$339 -9 -26%
AF
203
Allworth Financial
California
$683 +$75 +2 +13%
JWA
204
JFS Wealth Advisors
Pennsylvania
$643 – – –
QCG
205
Quadrant Capital Group
Ohio
$643 +$602 +16 New
PA
206
Parallel Advisors
California
$482 – – –
TWD
207
True Wealth Design
Ohio
$362 – – –
SPIA
208
Steward Partners Investment Advisory
New York
$361 – – –
IA
209
IFP Advisors
Florida
$241 +$226 +6 New
WANY
210
Wealthspire Advisors (New York)
New York
$241 +$226 +6 New
FFO
211
Fortitude Family Office
Arizona
$201 – – –
SS
212
SBI Securities
Japan
$161 +$38 +1 +33%
BHWM
213
Bay Harbor Wealth Management
Maryland
$120 +$38 +1 +50%
HIA
214
HFM Investment Advisors
New Jersey
$120 +$75 +2 +200%
RWM
215
Rialto Wealth Management
New York
$81 – – –
SIC
216
SJS Investment Consulting
Ohio
$81 +$38 +1 +100%
Jones Financial Companies
217
Jones Financial Companies
Missouri
$39 – – –
DPW
218
DiNuzzo Private Wealth
Pennsylvania
$38 – – –
O
219
OrbiMed
New York
– -$18.6M -557,900 Closed
CP
220
CenterBook Partners
Connecticut
– -$8.08M -243,063 Closed
Axa
221
Axa
France
– -$7.5M -225,367 Closed
Nordea Investment Management
222
Nordea Investment Management
Sweden
– -$7.52M -224,746 Closed
Voloridge Investment Management
223
Voloridge Investment Management
Florida
– -$6.23M -187,395 Closed
CF
224
Cantor Fitzgerald
New York
– -$4.46M -134,200 Closed
CC
225
Casdin Capital
New York
– -$3.33M -100,000 Closed
7 8
9
10 11

AGIO Hedge Fund Activity: Q3 2025 in Review

220 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2025, worth a combined $2.55B — up 24% from $2.05B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new AGIO positions and 35 closed out — a net gain of 8 holders — while 68 added to existing stakes and 69 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $77.1M. The largest seller was JP Morgan Chase, cutting an estimated $31.8M.

  • 220 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2025, up from 214 in Q2 2025.
  • Funds reported $2.55B of Agios Pharmaceuticals stock for Q3 2025, up 24% quarter-over-quarter.
  • 43 funds opened new Agios Pharmaceuticals positions in Q3 2025 and 35 closed out, a net change of +8 holders.
  • The largest Agios Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $77.1M added.
  • The largest Agios Pharmaceuticals seller in Q3 2025 was JP Morgan Chase, an estimated $31.8M sold.

Based on aggregated 13F filings for Q3 2025.